Low Testosterone Levels and Grade Group Progression Among Localized Prostate Cancer Patients on Active Surveillance: A Retrospective Cohort Study
These findings suggest that while low testosterone is not clearly associated with moderate progression (GG2), it may increase the risk of higher-grade "extreme" progression to GG3 or higher. Future studies should focus on prospective validation of our findings to elucidate the biological relationship between androgens and prostate cancer progression.
Authors
- Margaux Robert
- Andrew Warren Hahn (ORCID: https://orcid.org/0000-0002-4153-205X)
- Louis L. Pisters (ORCID: https://orcid.org/0000-0002-9226-6062)
- John F. Ward (ORCID: https://orcid.org/0000-0001-6027-8774)
- Matthew Smith (ORCID: https://orcid.org/0000-0003-0087-7817)
- Noel Higgason (ORCID: https://orcid.org/0000-0002-6419-0726)
- Tarek Lawen (ORCID: https://orcid.org/0000-0002-2290-062X)
- Brian F. Chapin (ORCID: https://orcid.org/0000-0003-3225-9976)
- Peng Wei
- Jeissen Pyo
- Rachel Garcia
- Daniel E. Frigo
- Carrie R. Daniel
- Lisly S. Chery
- Curtis A. Pettaway
- John W. Davis
- Justin R. Gregg
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- The Journal of Urology
- Published
- 2026-02-09
- DOI
- https://doi.org/10.1097/ju.0000000000004986
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00